November 2007
Advantage acquires Pender NDI Life Science (VCC) Fund, which it renames the Advantage Life Science Fund II.  Advantage Life Science Fund II has $13 million in net assets and has an annual tax credit allocation of $7 million. When combined with its other funds, this acquisition provides Advantage with aggregate net asset of over $75 million and the ability to raise $20 million of tax credit allocations each year.

May 2007
Advantage Technology Fund portfolio company Parasun Technologies is acquired by Uniserve Communications Corp. (TSXV:USS) for $12.5 million in cash plus a working capital distribution, providing Advantage with a realized return of 4.6 times invested capital. Further post acquisition payments increase the purchase price to $14.5 million and a realized return of 5.5 times invested capital.

May 2007
Advantage Technology Fund portfolio company Brightside Technologies is acquired by Dolby Laboratories (NYSE:DLB) for $30.4 million in cash, providing Advantage with a realized return of 2.8 times invested capital.

February 2007
Advantage receives additional 2006 tax credit allocations from the Investment Capital Branch and raises an aggregate of $13.4 million for the 2006 program year.

December 2006
Advantage declares and pays a special dividend of $10.00 per share to the shareholders of the Advantage Life Science Fund I, in order to distribute excess cash on hand.

August 2006
It is announced that the Advantage Life Science Fund I has provided its investors with the highest one year, three year and five year returns of any retail venture capital fund in Canada.

August 2006
Advantage receives the Canadian Venture Capital Association 'Deal of the Year' Award for achieving the highest realized return on a single investment (Aspreva Pharmaceuticals) of any institutional or retail venture fund in Canada that year.

April 2006
Advantage completes the sale of its stock in Aspreva Pharmaceuticals for aggregate proceeds of $5.4 million, providing the Advantage Life Science Fund I with a realized return of 23.4 times invested capital.

February 2006
Advantage raises its full $10 million tax credit allocation for 2005 by February 17, 2006.

January 2005
Advantage raises its full $10 million tax credit allocation for 2004 by January 15, 2005.

November 2004
The Advantage Technology Fund raises an aggregate of $10 million and is closed. At the request of Dr. Basil Peters, the then manager of the Advantage Technology Fund, the Board of Advantage subsequently transfers $5 million from the Advantage Technology Fund to the Advantage Venture Fund in April 2005.

September 2004
As substantially all investors in Advantage have historically chosen to make a diversified investment that was split evenly between the two funds, the Board of Advantage broadens the mandate of the life science fund to include both technology and life science investments and renames it the 'Advantage Venture Fund'. The Board agrees that the Advantage Technology Fund will continue to focus its investments in technology companies and caps that fund at $10 million.

August 2004
Advantage merges with Qwest Emerging Biotech (VCC) Ltd. and the Qwest shareholders exchange their shares of Qwest for shares of the Advantage Life Science Fund I.

February 2004
Advantage raises $12.4 million of tax credit allocation for 2003 prior to its sales being halted by the Investment Capital Branch on February 6, 2004.

November 2003
Advantage receives a record breaking $2.1 million of orders for its shares on its first day of sales.

November 2003
Don Rix, Frank Holler, Jim Heppell, David Raffa and Ray Matthews co-found BC Advantage Funds (VCC) Ltd. Advantage offers investors the opportunity to invest in a dedicated life sciences fund, and dedicated technology fund, or to make a diversified investment that is split evenly between the two funds.

October 2003
Qwest sells its shares in Xillix Technologies, which provides it with a realized return of 3.0 times invested capital.

September 2001
Ray Matthews and Jim Heppell co-found Qwest Emerging Biotech (VCC) Ltd. Qwest raises funds and invests in five BC life science companies.